AMBER ALLAN: Open Payments
NPI 1285331454 · HOUMA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$890 in 16 payments from 12 companies in 2025. Trend: 2023 $107 · 2024 $424 · 2025 $890
Food & beverage: $890
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 2 | $227 |
| Dexcom, Inc. | 2 | $184 |
| GlaxoSmithKline, LLC. | 3 | $136 |
| Abbott Laboratories | 1 | $130 |
| Actelion Pharmaceuticals US, Inc. | 1 | $86 |
| Novo Nordisk Inc | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $19 |
| PFIZER INC. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
Products named: DEXCOM G7 GSS (161), ETERNA, AIRSUPRA, UPTRAVI, TRELEGY ELLIPTA, Ozempic, MOUNJARO, Dexcom G6 Transmitter.
Industry payments across LA — which companies pay providers there.
